Kardigan Raises $254M Series B to Advance Cardiovascular Drug Development

Deal Summary

Kardigan closed a $254M Series B to advance its cardiovascular drug development efforts. Lead and participating backers include Fidelity Management & Research Company, accounts advised by T. Rowe Price Investment Management, ARCH Venture Partners and Sequoia Heritage.